Health Condition 1: I248- Other forms of acute ischemic heart disease
Conditions
Interventions
Intervention1: BioMimeââ??¢ Morph Sirolimus Eluting Coronary Stent (SES) System: Patients with symptomatic ischemic heart disease due to de novo lesions (lengths Ã?â??
45 mm) in native coronary arte
Sponsors
SMC Heart Institute and IVF Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: Patients with symptomatic ischemic heart disease who were implanted with BioMimeââ??¢ Morph SES System between 1st January 2021 and 31st December 2022.
Exclusion criteria
Exclusion criteria: As this is a retrospective study, there are no formal exclusion criteria for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Target Lesion Failure (TLF): Defined as the composite of cardiovascular death, target vessel myocardial infarction (TV-MI) and target lesion revascularization (TLR)Timepoint: 1 Year | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Cardiovascular death [Time Frame: Through 1 year] 2. Target Vessel Myocardial Infarction (TV-MI) [Time Frame: Through 1 year] 3. Target Lesion Revascularization (TLR) [Time Frame: Through 1 year] 4. Target Vessel Failure (TVF) [Time Frame: Through 1 year] 5. Target Vessel Revascularization (TVR) [Time Frame: Through 1 year] 6. Stent Thrombosis [Time Frame: Through 1 year] 7. Stroke [Time Frame: Through 1 year] 8. Procedure success [Time Frame: At Discharge] 9. Device success [Time Frame: During procedure] 10. Length of Hospital Stay [Time Frame: At Discharge]Timepoint: 1 Year | — |
Countries
India
Contacts
Public ContactDr Satish Suryavanshi
SMC Heart Institute and IVF Research Centre
Outcome results
None listed